Literature DB >> 20814829

Targeting head and neck squamous cell carcinoma using a novel fusion toxin-diphtheria toxin/HN-1.

Sirisha Potala1, Rama S Verma.   

Abstract

The current treatment strategies, chemotherapy and radiation therapy being used for the management of cancer are deficient in targeted approach leading to treatment related toxicities and relapse. Contrarily, fusion toxins exhibit remarkable tumor specificity thus emerging as an alternative therapy for the treatment of cancer. Diphtheria toxin-HN-1 peptide (DT/HN-1) is a fusion toxin designed to target the head and neck squamous cell carcinoma (HNSCC). The aim of this study was to construct, characterize, and evaluate the cytotoxicity and specificity of DT/HN-1 fusion toxin against the HNSCC cells. The purified DT/HN-1 fusion toxin was characterized by SDS-PAGE and western blotting. Refolding of purified fusion toxins was monitored by fluorescence spectra and circular dichroism spectra. The activity of DT/HN-1 fusion toxin was demonstrated on various HNSCC cell lines by cell viability assay, cell proliferation assay, protein synthesis inhibition assay, apoptosis and cell cycle analysis. The fusion toxin DT/HN-1 demonstrated remarkably high degree of cytotoxicity specific to the HNSCC cells. The IC(50) of DT/HN-1 fusion toxin was ~1 to 5 nM in all the three HNSCC cell lines. The percentage apoptotic cells in DT/HN-1 treated UMB-SCC-745 cells are 16% compared to 4% in untreated. To further demonstrate the specific toxicity of DT/HN-1 fusion toxin towards the HNSCC cells we constructed, characterized and evaluated the efficacy of DT protein. The DT protein coding for only a fragment of diphtheria toxin without its native receptor binding domain failed to exhibit any cytotoxicity on all the cell lines used in this study thus establishing the importance of a ligand in achieving targeted toxicity. To evaluate the translocation ability of HN-1 peptide, an additional construct DTΔT/HN-1 was constructed, characterized and evaluated for its cytotoxic activity. The fusion toxin DTΔT/HN-1 deficient of the translocation domain of diphtheria toxin showed no cytotoxicity on all the cell lines clearly indicating the inability of HN-1 peptide to translocate catalytic domain of the toxin into the cytosol.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20814829     DOI: 10.1007/s11033-010-0242-8

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  25 in total

1.  The crystal structure of diphtheria toxin.

Authors:  S Choe; M J Bennett; G Fujii; P M Curmi; K A Kantardjieff; R J Collier; D Eisenberg
Journal:  Nature       Date:  1992-05-21       Impact factor: 49.962

2.  Uptake of diphtheria toxin and its fragment A moiety by mammalian cells in culture.

Authors:  C B Saelinger; P F Bonventre; B Ivins; D Straus
Journal:  Infect Immun       Date:  1976-09       Impact factor: 3.441

3.  Characterization and receptor specific toxicity of two diphtheria toxin-related interleukin-3 fusion proteins DAB389-mIL-3 and DAB389-(Gly4Ser)2-mIL-3.

Authors:  D Liger; J C vanderSpek; C Gaillard; C Cansier; J R Murphy; P Leboulch; D Gillet
Journal:  FEBS Lett       Date:  1997-04-07       Impact factor: 4.124

4.  Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.

Authors:  E Olsen; M Duvic; A Frankel; Y Kim; A Martin; E Vonderheid; B Jegasothy; G Wood; M Gordon; P Heald; A Oseroff; L Pinter-Brown; G Bowen; T Kuzel; D Fivenson; F Foss; M Glode; A Molina; E Knobler; S Stewart; K Cooper; S Stevens; F Craig; J Reuben; P Bacha; J Nichols
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

5.  Assessment of microsatellite instability in head and neck cancer using consensus markers.

Authors:  Zubeyde Yalniz; Semra Demokan; Yusufhan Suoglu; Murat Ulusan; Nejat Dalay
Journal:  Mol Biol Rep       Date:  2010-02-25       Impact factor: 2.316

Review 6.  Induction of apoptosis by tumor cell-targeted toxins.

Authors:  A Thorburn; J Thorburn; A E Frankel
Journal:  Apoptosis       Date:  2004-01       Impact factor: 4.677

Review 7.  Current aspects of targeted therapy in head and neck tumors.

Authors:  Andreas Dietz; Andreas Boehm; Christian Mozet; Gunnar Wichmann; Athanassios Giannis
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-07       Impact factor: 2.503

8.  ADP-ribosylation of elongation factor 2 by diphtheria toxin. Isolation and properties of the novel ribosyl-amino acid and its hydrolysis products.

Authors:  B G Van Ness; J B Howard; J W Bodley
Journal:  J Biol Chem       Date:  1980-11-25       Impact factor: 5.157

Review 9.  Targeted therapies in squamous cell carcinoma of the head and neck.

Authors:  Kathryn A Gold; Ho-Young Lee; Edward S Kim
Journal:  Cancer       Date:  2009-03-01       Impact factor: 6.860

Review 10.  Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas.

Authors:  Michael Weaver; Douglas W Laske
Journal:  J Neurooncol       Date:  2003-10       Impact factor: 4.130

View more
  3 in total

1.  Biological Evaluation of a Fluorescent-Imaging Agent for Medullary Thyroid Cancer in an Orthotopic Model.

Authors:  Kara K Rossfeld; Steven E Justiniano; Haiming Ding; Li Gong; Shankaran Kothandaraman; Dwitiya Sawant; Motoyasu Saji; Chadwick L Wright; Lawrence S Kirschner; Matthew D Ringel; Michael F Tweedle; John E Phay
Journal:  J Clin Endocrinol Metab       Date:  2017-09-01       Impact factor: 5.958

2.  Tumor specifically internalizing peptide 'HN-1': Targeting the putative receptor retinoblastoma-regulated discoidin domain receptor 1 involved in metastasis.

Authors:  Frank-Un Hong; Miguel Castro; Klaus Linse
Journal:  World J Clin Oncol       Date:  2022-05-24

Review 3.  Advancing theranostics with tumor-targeting peptides for precision otolaryngology.

Authors:  Chadwick L Wright; Quintin Pan; Michael V Knopp; Michael F Tweedle
Journal:  World J Otorhinolaryngol Head Neck Surg       Date:  2016-07-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.